These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 33154717)

  • 1. Changes in Day/Night Activity in the 6-OHDA-Induced Experimental Model of Parkinson's Disease: Exploring Prodromal Biomarkers.
    Requejo C; López-de-Ipiña K; Ruiz-Ortega JÁ; Fernández E; Calvo PM; Morera-Herreras T; Miguelez C; Cardona-Grifoll L; Cepeda H; Ugedo L; Lafuente JV
    Front Neurosci; 2020; 14():590029. PubMed ID: 33154717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pirouetting pigs: A large non-primate animal model based on unilateral 6-hydroxydopamine lesioning of the nigrostriatal pathway.
    Christensen AB; Sørensen JCH; Ettrup KS; Orlowski D; Bjarkam CR
    Brain Res Bull; 2018 May; 139():167-173. PubMed ID: 29462643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of BDNF/TrkB signaling in the effect of diphenyl diselenide on motor function in a Parkinson's disease rat model.
    Sampaio TB; Pinton S; da Rocha JT; Gai BM; Nogueira CW
    Eur J Pharmacol; 2017 Jan; 795():28-35. PubMed ID: 27915043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanodelivery of Cerebrolysin and Rearing in Enriched Environment Induce Neuroprotective Effects in a Preclinical Rat Model of Parkinson's Disease.
    Requejo C; Ruiz-Ortega JA; Cepeda H; Sharma A; Sharma HS; Ozkizilcik A; Tian R; Moessler H; Ugedo L; Lafuente JV
    Mol Neurobiol; 2018 Jan; 55(1):286-299. PubMed ID: 28840482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of unilateral and bilateral intrastriatal 6-hydroxydopamine-induced axon terminal lesions: evidence for interhemispheric functional coupling of the two nigrostriatal pathways.
    Roedter A; Winkler C; Samii M; Walter GF; Brandis A; Nikkhah G
    J Comp Neurol; 2001 Apr; 432(2):217-29. PubMed ID: 11241387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.
    Yue X; Hariri DJ; Caballero B; Zhang S; Bartlett MJ; Kaut O; Mount DW; Wüllner U; Sherman SJ; Falk T
    Neuroscience; 2014 Jan; 258():385-400. PubMed ID: 24291725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease.
    Voutilainen MH; Bäck S; Pörsti E; Toppinen L; Lindgren L; Lindholm P; Peränen J; Saarma M; Tuominen RK
    J Neurosci; 2009 Jul; 29(30):9651-9. PubMed ID: 19641128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-lesion administration of 7-NI attenuated motor and non-motor deficits in 6-OHDA induced bilaterally lesioned female rat model of Parkinson's disease.
    Kumari R; Kumar JB; Luthra PM
    Neurosci Lett; 2015 Mar; 589():191-5. PubMed ID: 25528406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective and therapeutic activity of honokiol in reversing motor deficits and neuronal degeneration in the mouse model of Parkinson's disease.
    Chen HH; Chang PC; Chen C; Chan MH
    Pharmacol Rep; 2018 Aug; 70(4):668-676. PubMed ID: 29909247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between Tail Suspension Swing Test and Standard Rotation Test in Revealing Early Motor Behavioral Changes and Neurodegeneration in 6-OHDA Hemiparkinsonian Rats.
    Rosa I; Di Censo D; Ranieri B; Di Giovanni G; Scarnati E; Alecci M; Galante A; Florio TM
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats.
    Jin F; Wu Q; Lu YF; Gong QH; Shi JS
    Eur J Pharmacol; 2008 Dec; 600(1-3):78-82. PubMed ID: 18940189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracarotid Infusion of Mesenchymal Stem Cells in an Animal Model of Parkinson's Disease, Focusing on Cell Distribution and Neuroprotective and Behavioral Effects.
    Cerri S; Greco R; Levandis G; Ghezzi C; Mangione AS; Fuzzati-Armentero MT; Bonizzi A; Avanzini MA; Maccario R; Blandini F
    Stem Cells Transl Med; 2015 Sep; 4(9):1073-85. PubMed ID: 26198165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats.
    Pang Y; Lin S; Wright C; Shen J; Carter K; Bhatt A; Fan LW
    Neuroscience; 2016 Mar; 318():157-65. PubMed ID: 26777890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed-ratio discrimination training as replacement therapy in Parkinson's disease: studies in a 6-hydroxydopamine-treated rat model.
    Van Keuren KR; Stodgell CJ; Schroeder SR; Tessel RE
    Brain Res; 1998 Jan; 780(1):56-66. PubMed ID: 9473587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regenerative effects of peptide nanofibers in an experimental model of Parkinson's disease.
    Sever M; Turkyilmaz M; Sevinc C; Cakir A; Ocalan B; Cansev M; Guler MO; Tekinay AB
    Acta Biomater; 2016 Dec; 46():79-90. PubMed ID: 27619838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a new low-dose 6-hydroxydopamine model of Parkinson's disease in rat.
    Penttinen AM; Suleymanova I; Albert K; Anttila J; Voutilainen MH; Airavaara M
    J Neurosci Res; 2016 Apr; 94(4):318-28. PubMed ID: 26762168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.
    Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A
    PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.